Simone Bauer
German Cancer Research Center
6 Papers
9 Citations
Simone Bauer is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
Arlou Kristina Angeles,Florian Janke,Simone Bauer,Petros Christopoulos,Anja Lisa Riediger,Holger Sültmann +5 more
TL;DR: In this paper, the authors highlight the potential of deep characterization of tumor cfDNA genomics and fragmentomics as well as nucleosome modifications (chromatin structure), and methylation patterns (epigenomics) for comprehensive and multi-modal assessment of cfDNA.
24
Genome-Based Classification and Therapy of Prostate Cancer
Arlou Kristina Angeles,Simone Bauer,Leonie Ratz,Sabine M. Klauck,Holger Sültmann +4 more
- 02 Sep 2018
TL;DR: The utility and limitations of current clinical practices to diagnosis, prognosis, and therapy are recapitulate, and examples of insights generated by the molecular profiling of tumors are provided.
22
DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer.
Yuri Tolkach,Romina Zarbl,Simone Bauer,Manuel Ritter,Jörg Ellinger,Stephan Hauser,Laura Hüser,Sabine M. Klauck,Peter Altevogt,Holger Sültmann,Dimo Dietrich,Glen Kristiansen +11 more
TL;DR: It is suggested that promoter DNA methylation of the CD24 gene and T2E fusion status are factors involved in the upregulation of CD24 in patients with PCa.
8
miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells.
Simone Bauer,Leonie Ratz,Doreen Heckmann-Nötzel,Adam Kaczorowski,Markus Hohenfellner,Glen Kristiansen,Stefan Duensing,Peter Altevogt,Sabine M. Klauck,Holger Sültmann +9 more
TL;DR: In this article, the role of epigenomic alterations associated with T2E+ PCa was investigated using different sequencing cohorts, and it was found that several transcripts of the miR-449 cluster to be repressed in prostate cancer (PCa) patients.
7
Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma
Paula Hoffmeister,Andreas Mock,Federico Nichetti,Felix Korell,Christoph Heining,Anna-Lena Scherr,M. Günther,Thomas Albrecht,E. Kelmendi,Kuangfeng Xu,L. Nader,A. Kessler,N. Schmitt,Sarah Fritzsche,S Weiler,B Sobol,Albrecht Stenzinger,Stefan Boeck,C. Benedikt Westphalen,Klaus Schulze-Osthoff,Joerg Trojan,Thomas Kindler,Wilko Weichert,Karsten Spiekermann,Monika Bitzer,Gunnar Folprecht,Anna Lena Illert,Melanie Boerries,Frederick Klauschen,S. Ochsenreiter,Jens T. Siveke,Simone Bauer,Hanno Glimm,Benedikt Brors,Jennifer Hüllein,Daniel Hübschmann,Sebastian Uhrig,Peter Horak,Simon Kreutzfeld,Jesus M. Banales,Christoph Springfeld,Diana Jäger,Peter Schirmacher,Sabine Roessler,Steffen Ormanns,Benjamin Goeppert,Stefan Fröhling,Bruno Köhler +47 more
TL;DR: Observations identify Bcl-xL as a key protein in cell death resistance of CCA and may pave the way for clinical application, as well as indicating a prognostic value of Bcl -xL in CCA depending on the CCA subtype.